Bropirimine

Overview

Bropirimine (U-54461; U-54461S; PNU-54461) is an orally active TLR7 agonist. Bropirimine inhibits RANKL-induced osteoclast differentiation of mouse bone marrow-derived macrophages (BMMs). Bropirimine exhibits dose-dependent direct inhibitory effects on colony formation of cultured KK-47 and 724 cells. Bropirimine can be used for the study of cancers and bone metabolic disorders such as osteoporosis.

Application

Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Autoimmune Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer | Products > Signaling Pathways > Toll-like Receptor (TLR)

Product Information

• Catalog No.: HY-W008634
• CAS No.: 56741-95-8
• Molecular Formula: C10H8BrN3O
• Molecular Weight: 266.10
• Purity: 99.94%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.08 mg/mL (7.82 mM); Clear solution
• Availability: In-stock

Source

Original product source